Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target

Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO

0.00

Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ: ZBIO) with a Outperform and maintains $45 price target.